Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP)

Cancer

Volumn 92, Issue 3, 2001, Pages 650-656

  Parra, Héctor Soto ^a   Tixi, Lucia ^b   Latteri, Fiorenza ^c   Bretti, Sergio ^d   Alloisio, Marco ^e   Gravina, Adriano ^a   Lionetto, Rita ^b   Bruzzi, Paolo ^c   Dani, Carla ^d   Rosso, Riccardo ^e   Cosso, Maurizio ^c   Balzarini, Luca ^a   Santoro, Armando ^d   Ardizzoni, Andrea ^e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Gruppo Italiano Tumori Rari (Italian Group on Rare Tumors)   (Italy)

^c Istituto Nazionale Tumori   (Italy)

^d Forza Operativa Italiana Contro il Cancro del Polmone (The Italian Lung Cancer Task Force)   (Italy)

^e Ospedale di Ivrea   (Italy)

Author keywords

Chemotherapy; Cisplatin; Combined modalities; Doxorubicin; Immunotherapy; Interferon; Malignant mesothelioma

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035423907     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0     Document Type: Article

References (48)

1. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers
2. Natural history and epidemiology of malignant mesothelioma
3. IARC-WHO cancer incidence in five continents
4. Health implications of environmental exposure to asbestos
5. The role of surgery in diffuse malignant mesothelioma of the pleura
6. The role of extrapleural pneumonectomy in malignant pleural mesothelioma
7. Chemotherapy in malignant pleural mesothelioma. A review
8. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study
9. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: A phase II FONICAP trial. Italian Lung Cancer Task Force
10. Chemosensitivity and cytokine sensitivity of malignant mesothelioma
11. Interferon-alpha and -gamma in combination with chemotherapeutic drugs: In vitro sensitivity studies in four human mesothelioma cell lines
12. Interferon therapy for neoplastic disease in man in vitro and in vivo
13. Effect of interferon alpha 2a on malignant mesothelioma
14. Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice
15. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma
16. A proposed new international TNM staging system for malignat pleural mesothelioma. From the International Mesothelioma Interest Group
17. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
18. Reporting results of cancer treatment
19. Optimal two stage designs for phase II clinical trials
20. Non parametric estimation from incomplete observation
21. Benign and malignant mesothelioma
22. Chemotherapy for malignant mesothelioma: A quantitative and qualitative overview of the literature
23. The interferons: Mechanisms of action and clinical applications
24. Antineoplastic activity of combination of interferon and cytotoxic agents against experimental and human malignancies: A review
25. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma
26. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma
27. Inhibition of angiogenesis by interferons: Effects of tumor- and lymphocyte-induced vascular responses
28. Inhibition of cell motility by interferon
29. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fribroblasts of nude mice
30. Human recombinant interferons B and Y decrease gelatinase production and invasion by human KG-2 renal carcinoma cells
31. Suppression of gelatinase production with decreased invasiveness of chorio-carcinoma cells by human recombinant interferon-beta
32. Isolation and characterization of metastic variants form human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice
33. Interferons alpha and beta downregulate the expression of basic fibroblast growth facto in human renal cell carcinoma cells
34. Interferon-alpha-mediated downreguation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of dose and schedule
35. Evaluation of low-dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: A Southwest Oncology Group study
36. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
37. Prospective randomized trial of two dose levels of interferon-alpha with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trial Network study
38. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a
39. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma
40. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma
41. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon
42. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma
43. Immunotherapy of SV40 induced tumours in mice: A model for vaccine development
44. Simina virus 40, poliovaccines and human tumors: A review of recent development
45. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
46. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study
47. Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial
48. The combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study